Definitive Contract HHSD200201896321C
Award Date
2/27/18
Potential Completion Date
2/26/19
Potential Value
$27M
Funding Federal Agency
CDC Pittsburgh
Contracting Federal Agency
Office of the Assistant Secretary for Preparedness and Response
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $600,822,821 definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Emergent Biosolutions Canada Inc. for the supply of VIGIV (vaccinia immune globulin) and associated services. The contract is a follow-on to previous CDC contracts and is not a small business set-aside. The contract requires Emergent to provide 22,050 vials of VIGIV to the Strategic National Stockpile, as well as services such as stability testing, shelf life...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded an Other Transaction Agreement to Emergent Biosolutions Canada Inc. valued at $34.6 million to support the development of human immune globulin (COVID-HIG) manufactured from human plasma with antibodies to SARS-CoV-2. The contract aims to prevent coronavirus disease (COVID-19) through October 2022. Performance will take place at Emergent Biosolutions Canada Inc.'s facility in Ottawa,...
This firm fixed-price contract, valued at $762,812,695, was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company. The contract is for the development of medical countermeasures (MCM) that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This federal contract award is for BAXTER CELL HARVEST services in year 6 of the contract, awarded by the Centers for Disease Control and Prevention (CDC) Pittsburgh to Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense. The contract has a ceiling value of $38,250,000.00 and was awarded on September 30, 2016, with an ultimate completion date of August 31, 2018. It is a Firm Fixed Price delivery order contract. Emergent Biodefense is a for-profit manufacturer of...
This is a $748,857,151.46 firm fixed-price contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer, to develop and deliver the ACAM2000 smallpox (vaccinia) vaccine over a 10-year period. The contract was awarded on a sole-source basis as Emergent is the only FDA-licensed provider of ACAM2000. This contract does not have a set-aside...
<p>This is a firm fixed-price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Cangene Corporation on May 30, 2006. The contract has a ceiling value of $594,219,525.00 and a completion date of December 31, 2027. The place of performance is in Ottawa, Canada. The contract does not have a set-aside designation.</p>
This contract award, valued at $37,890,000, was issued by the Centers for Disease Control and Prevention (CDC) to Emergent BioDefense Operations Lansing LLC for the delivery of ACAM 2000 vaccines. ACAM 2000 is the only Food and Drug Administration (FDA)-licensed vaccine for the prevention of smallpox disease, a critical component of the U.S. government's strategic national stockpile. The contract, awarded on September 30, 2015, is a firm-fixed-price delivery order with an ultimate completion...
This is a $19,763,563.00 cost-plus-fixed-fee delivery order contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract was awarded to Emergent Manufacturing Operations Baltimore LLC, a for-profit limited liability company and manufacturer of goods registered in the System for Award Management (SAM). The contract is part of the Centers for Innovation in Advanced...
<p>This is a contract awarded by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to Emergent Biodefense Operations Lansing LLC, also known as Emergent Biodefense, for the maintenance of a smallpox license. The contract is a delivery order with a firm fixed price of $38,430,000.00 and a completion date of January 31, 2019. The place of performance is located in Cambridge, Massachusetts. The contract does not have a set-aside designation.</p>